Table 3. Univariate and multivariate Cox regression analyses predicting biochemical recurrence in the Validation-TMA series.
| Parameter | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| HR (95% CI) | p-Value | HR (95% CI) | p-Value | |
| Preoperative PSA | 1.03 (1.03–1.04) | <0.001 | 1.02 (1.01–1.03) | <0.001 |
| pT | 2.60 (2.20–3.07) | <0.001 | 1.44 (1.18–1.74) | <0.001 |
| RP Gleason score | 1.95 (1.78–2.13) | <0.001 | 1.67 (1.51–1.85) | <0.001 |
| Margin status | 2.36 (1.96–2.85) | <0.001 | 1.71 (1.40–2.10) | <0.001 |
| Benign adjacent tissue | ||||
| p65 continuous | 0.99 (0.95–1.03) | 0.645 | 1.00 (0.97–1.04) | 0.779 |
| p65 >3% versus ≤3% | 1.06 (0.86–1.30) | 0.575 | 1.13 (0.92–1.40) | 0.249 |
| Tumor tissue | ||||
| p65 continuous | 1.03 (1.02–1.04) | <0.001 | 1.02 (1.00–1.03) | 0.004 |
| p65 >3% versus ≤3% | 1.60 (1.32–1.94) | <0.001 | 1.33 (1.09–1.62) | 0.005 |
Significant p-values given in bold.
95% CI, 95% confidence interval; HR, hazard ratio; PSA, prostate-specific antigen; pT, pathological staging of the primary tumor; RP, radical prostatectomy.